Log In Sign up
The largest database of trusted experimental protocols

Tgf β inhibitor

Manufactured by Cayman Chemical
Visit Supplier

The TGF-β inhibitor is a laboratory product that functions to inhibit the activity of the Transforming Growth Factor-beta (TGF-β) signaling pathway. TGF-β is a multifunctional cytokine that regulates various cellular processes, including cell growth, differentiation, and immune response. This inhibitor can be used in research applications to study the role of the TGF-β pathway in biological systems.

Automatically generated - may contain errors

Lab products found in correlation

Interleukin 6 (il 6), by Thermo Fisher Scientific (3 mentions) Vascular endothelial growth factor (vegf), by Thermo Fisher Scientific (3 mentions) Stem cell factor (scf), by Thermo Fisher Scientific (3 mentions) Fibroblast growth factor 2 (fgf2), by Thermo Fisher Scientific (3 mentions) Lithium chloride (licl), by Merck Group (3 mentions) Bone morphogenetic protein 4 (bmp4), by Thermo Fisher Scientific (3 mentions) Interleukin 3 (il 3), by Thermo Fisher Scientific (3 mentions) Activin a, by Thermo Fisher Scientific (3 mentions) Mtesr1 media, by WiCell (3 mentions) H9 hesc wa09 line, by WiCell (2 mentions) Rock inhibitor, by Cayman Chemical (2 mentions) Rock inhibitor y27632, by Cayman Chemical (1 mentions) Matrigel, by WiCell (1 mentions)

Spelling variants of this product

TGF-β (7 citations) TGF-β inhibitor SB431542 (3 citations)

3 protocols using tgf β inhibitor

1

Directed Differentiation of hPSCs to Hematopoietic Lineages

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
hPSCs (H9 hESC (WA09) line from WiCell), iSOX17 H9 line and knockout SOX17 H9 line were maintained and passaged on Matrigel in mTeSR1 media (WiCell). The cell lines were differentiated on collagen IV (ColIV)-coated plate (Uenishi et al., 2014 (link)). Cell lines were plated at a density of 5,000 cells/cm2 onto 6 well plates with E8 media containing 10 μM Rock inhibitor (Y-27632, Cayman Chemicals). The following day, the media was changed to IF9S media with 50 ng/ml FGF2 (PeproTech), 50 ng/ml BMP4 (PeproTech), 15 ng/ml Activin A (PeproTech), and 2 mM LiCl (Sigma), and cultured in hypoxia (5% CO2, 5% O2). On day 2, the media was changed to IF9S media with 50 ng/ml FGF2, 50 ng/ml VEGF (PeproTech), and 2.5 μM TGF-β inhibitor (SB-431542, Cayman), and cultured in hypoxia (5% CO2, 5% O2). On days 4 and 6, the media was changed to IF9S media with 50 ng/ml FGF2, 50 ng/ml VEGF, 50 ng/ml TPO (PeproTech), 50 ng/ml IL-6 (PeproTech), 20 ng/ml SCF (PeproTech), and 10 ng/ml IL-3 (PeproTech), and cultured in normoxia (5% CO2, 20% O2). DOX (Sigma) was added to cultures on day 2 of differentiation at concentration of 2 μg/ml.
Jung H.S., Uenishi G., Park M.A., Liu P., Suknuntha K., Raymond M., Choi Y.J., Thomson J.A., Ong I.M, & Slukvin I.I. (2021). SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. Cell reports, 34(7), 108758.
+ Open protocol
+ Expand
2

Hematopoietic Differentiation of hPSCs

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
hPSCs were maintained and passaged on Matrigel in mTeSR1 media (WiCell). Hematopoietic differentiation was performed on collagen IV (ColIV)-coated plates in chemically defined serum-free medium as described.14 (link) The iSOX18 H1 line from hPSCs (H1 hESC line from WiCell) was maintained and passaged on Matrigel in mTeSR1 media (WiCell). The cell lines were differentiated on a collagen IV (ColIV)-coated plate.14 (link) To initiate differentiation, cells were plated at 5,000 cells/cm2 onto 6 well plates with E8 media and 10 μM Rock inhibitor (Y-27632, Cayman Chemicals). This media was changed the following day to IF9S media with 50 ng/mL FGF2 (PeproTech), 50 ng/mL BMP4 (PeproTech), 15 ng/mL Activin A (PeproTech), and 2 mM LiCl (Sigma), and cells were cultured in hypoxia (5% CO2, 5% O2). On day 2, the media was changed to IF9S media with 50 ng/mL FGF2, 50 ng/mL VEGF (PeproTech), and 2.5 μM TGF-β inhibitor (SB-431542, Cayman), and cells were cultured in hypoxia (5% CO2, 5% O2). On days 4 and 6, the media was changed to IF9S media with 50 ng/mL FGF2, 50 ng/mL VEGF, 50 ng/mL TPO (PeproTech), 50 ng/mL IL-6 (PeproTech), 20 ng/mL SCF (PeproTech), and 10 ng/mL IL-3 (PeproTech), and cells were cultured in normoxia (20% CO2, 5% O2).
Jung H.S., Suknuntha K., Kim Y.H., Liu P., Dettle S.T., Sedzro D.M., Smith P.R., Thomson J.A., Ong I.M, & Slukvin I.I. (2023). SOX18-enforced expression diverts hemogenic endothelium-derived progenitors from T towards NK lymphoid pathways. iScience, 26(5), 106621.
+ Open protocol
+ Expand
3

Directed Differentiation of hPSCs to Hematopoietic Lineages

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
hPSCs (H9 hESC (WA09) line from WiCell), iSOX17 H9 line and knockout SOX17 H9 line were maintained and passaged on Matrigel in mTeSR1 media (WiCell). The cell lines were differentiated on collagen IV (ColIV)-coated plate (Uenishi et al., 2014 (link)). Cell lines were plated at a density of 5,000 cells/cm2 onto 6 well plates with E8 media containing 10 μM Rock inhibitor (Y-27632, Cayman Chemicals). The following day, the media was changed to IF9S media with 50 ng/ml FGF2 (PeproTech), 50 ng/ml BMP4 (PeproTech), 15 ng/ml Activin A (PeproTech), and 2 mM LiCl (Sigma), and cultured in hypoxia (5% CO2, 5% O2). On day 2, the media was changed to IF9S media with 50 ng/ml FGF2, 50 ng/ml VEGF (PeproTech), and 2.5 μM TGF-β inhibitor (SB-431542, Cayman), and cultured in hypoxia (5% CO2, 5% O2). On days 4 and 6, the media was changed to IF9S media with 50 ng/ml FGF2, 50 ng/ml VEGF, 50 ng/ml TPO (PeproTech), 50 ng/ml IL-6 (PeproTech), 20 ng/ml SCF (PeproTech), and 10 ng/ml IL-3 (PeproTech), and cultured in normoxia (5% CO2, 20% O2). DOX (Sigma) was added to cultures on day 2 of differentiation at concentration of 2 μg/ml.
Jung H.S., Uenishi G., Park M.A., Liu P., Suknuntha K., Raymond M., Choi Y.J., Thomson J.A., Ong I.M, & Slukvin I.I. (2021). SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis. Cell reports, 34(7), 108758.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!